Medicare ACCESS and FDA TEMPO: a new care pathway, not a proof-of-benefit badge

Medicare ACCESS can help pay for technology-supported chronic care; FDA TEMPO pilot participation does not establish that a device improves health.

That distinction matters when a parent is offered an app, coaching service or connected device carrying the name of a federal program. On July 22, the FDA announced its first TEMPO participant. The device pilot is linked to care expected to be covered under CMS’s ACCESS model.

Together, the programs create a route for testing a different way to deliver and pay for care. They do not turn a federal-program logo into a clinical recommendation for every patient.

Two programs answer different questions

ACCESS, which began July 5, is a voluntary, ten-year Original Medicare payment test. Participating care organizations receive recurring payments, with full payment tied to measurable health outcomes rather than a prescribed volume of activities.

TEMPO addresses the regulatory pathway for certain devices used in that care. Under defined circumstances, the FDA intends to exercise enforcement discretion for some requirements while participants collect and report real-world data. The agency explicitly says effectiveness for the pilot’s intended uses has not yet been evaluated by the FDA.

Neither statement is a shortcut around the other. A paid service may use a device whose effectiveness is still being evaluated; a device’s regulatory status alone cannot establish which care provider offers it or whether you qualify for the payment model.

Before enrollment, identify the care relationship

CMS’s referring-clinician guidance says ACCESS currently serves people with Original Medicare and complements existing care. Ask the participating organization which condition and track qualify, what services it provides, and what cost-sharing applies. Do not assume a private Medicare Advantage plan offers the same arrangement.

Then make responsibility concrete. Who reviews incoming measurements? How does the organization communicate with the usual clinician? What happens when needs change, a device reading is concerning or the service cannot manage the condition?

For a device offered under TEMPO, ask for its specific intended use and restrictions, not just whether the manufacturer appears on a list. The patient-facing explanation should make clear which evidence already exists and which outcomes the pilot still needs to establish.

These questions protect an existing care plan from becoming a collection of disconnected services. An elegant app does not resolve a missing handoff.

The payment incentive is promising—and worth examining

Outcome-linked payment gives providers a reason to show improvement instead of counting interactions. It could favor services that maintain support between appointments. It could also reward a convenient measured outcome while leaving the patient’s broader experience poorly captured. That is an analytical concern to test, not an allegation that participating organizations are doing so.

KFF’s July 7 analysis identifies an access constraint: beneficiaries may still need internet access or a suitable smartphone for technology-supported services. A care model that works for confident app users may be harder for someone who needs help with enrollment or connectivity.

Patients and caregivers could gain another source of ongoing support. Providers and technology companies gain a payment pathway. Patients poorly served by the chosen technology could lose time while navigating multiple teams, which makes clear accountability a practical requirement.

October 12 verification update: current CMS guidance schedules publication of organization-level risk-adjusted outcomes beginning in winter 2028. That future comparison will be more informative than participation alone. In the meantime, request existing evidence for the actual service and a clear explanation of its unresolved questions.

Frequently Asked Questions

Is ACCESS available to everyone with Medicare?

Current CMS guidance limits this model to Original Medicare, subject to qualifying conditions and participating-provider enrollment.

Does TEMPO selection mean FDA approval?

No. Selection involves a defined pilot and conditional enforcement discretion; it is not a general approval claim.

Are ACCESS and TEMPO the same program?

No. CMS tests payment and care delivery; the FDA pilot concerns certain devices used within the associated care pathway.

Will joining replace my regular doctor?

CMS describes ACCESS as complementary care. Confirm the organization’s coordination arrangements before enrollment.

Is the service necessarily free?

No. Cost-sharing can vary and may be waived by the participating organization. Ask about the exact track and service before agreeing.

What evidence should I request now?

Ask for evidence matching your condition, the actual service and its intended device use, plus a named clinician or team responsible for reviewing results.